Skip to main content

We are accepting new cases

Wegovy vs Ozempic

Wegovy and Ozempic are FDA-approved semaglutide drugs commonly used for weight loss. Learn about their differences and similarities.

Connect with an attorneyCheck Eligibility

Case Overview

Ozempic® and Wegovy® are both brand names of drugs that use semaglutide as an active ingredient. They’re classified as glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs. However, they have key differences, including what they’re intended to treat, their dosages and how they should be used. Learn more about the similarities and differences between Ozempic and Wegovy.

Working with Us

Wondering what happens when you submit a form or give us a call? We spend time gathering information from you, and your initial call is always free.

What's important?
  • Names
  • Dates
  • Timeline of events
  • Related documents
Connect with Us

or call: 1.800.768.4026

Wegovy vs Ozempic: Key takeaways

  • Wegovy and Ozempic are medications made by Novo Nordisk. Both contain the active ingredient semaglutide, are taken as weekly injections and are often used for weight loss.
  • The U.S. Food and Drug Administration (FDA) has approved Wegovy and Ozempic for different uses. Wegovy has FDA approval for treating obesity in overweight adults who have at least one weight-related health issue. Ozempic is approved for managing some conditions related to type 2 diabetes.
  • People have filed lawsuits alleging that taking semaglutide caused them to develop vision loss, intestinal blockages, other gastrointestinal issues, deep vein thrombosis and gallbladder disease. They also allege that drug manufacturers didn’t warn them of unlisted potential side effects.

Key differences between Wegovy and Ozempic

Though they share the same active ingredients, Wegovy and Ozempic share some differences. Many of these are related to how they’re used, doses and FDA approvals.

Approved uses

Ozempic and Wegovy have multiple approved uses. The FDA has approved Wegovy for chronic weight loss management to treat obesity and reduce the risk of certain cardiovascular diseases and events. Ozempic is also approved for the treatment of type 2 diabetes.

The FDA first approved Ozempic to reduce cardiovascular risk and manage blood glucose levels in patients with type 2 diabetes in December 2017. It’s generally administered as a weekly injection. Though Ozempic isn’t approved for weight loss, many physicians have also been prescribing this semaglutide drug as a weight-loss drug.

In June 2021, the FDA approved Wegovy for weight loss in adults who are obese or overweight with at least one weight-related health condition.

Wegovy FDA approvals

Ozempic FDA approvals

  • Improve Body Mass Index (BMI)

  • Maintain weight loss on a long-term basis

  • Reduce the risk of cardiovascular death and heart disease

  • Reduce the risk of heart attack

  • Reduce the risk of stroke

  • Improving glycemic control in patients with type 2 diabetes

  • Reducing the risk of heart disease

  • Reducing the risk of major adverse cardiovascular events in patients with type 2 diabetes

Cost and insurance coverage for Wegovy and Ozempic

During U.S. Senate committee meetings held in September 2024, federal lawmakers explained that Wegovy could cost as much as $1,349 per month, with Ozempic listed at $969 per month at that time.

Like most prescription medications, costs can vary depending on your insurance coverage. As of December 2025, the manufacturer’s list prices are:

  • Wegovy: $1,350 for a 28-day supply
  • Ozempic:  $1,000 – $1,200 for a one-month supply

Some insurance plans and other programs might reduce these costs. But the actual costs can get complicated, especially for off-label uses.

For example, Medicare currently covers Ozempic for use as a diabetes treatment but not for weight loss. That is expected to change in early 2027 after the federal government’s announcement about price cuts for Medicare recipients on 15 prescription drugs. Ozempic and Wegovy are on the list as an effort to reduce obesity.

Wegovy vs. Ozempic dosage

The dosage of the pre-filled single-use injections are another difference between Wegovy and Ozempic.

Wegovy dosage and method

  • Wegovy is usually injected with a pre-filled, single-use pen at 0.25 mg, increasing on a set schedule to the maximum injection dosage of 2.4 mg.
  • After four weeks, doctors may increase the dosage to 0.5 mg on weeks 5 – 8, 1.0 mg on weeks 9 – 12, 1.7 mg on weeks 13 – 16 and 2.4 mg on week 17 and every week after.

Ozempic dosage and method

  • Ozempic is usually injected with a pre-filled single-use pen at 0.25 mg – 2 mg per injection.
  • Treatment may continue with doctors increasing the dosage by 0.5 mg each week. The dosage maximum is 2.0 mg.
 

Initial weekly dosage

Maximum weekly dosage

Injection locations

Ozempic

.25 mg

2 mg

Upper arm, abdomen, thigh

Wegovy

.25 mg

2.4 mg

Upper arm, abdomen, thigh

 

Contact a semaglutide attorney

If you or a family member have experienced serious side effects from semaglutide, you might be eligible to seek compensation.

You can also reach our team by calling 1.800.768.4026.

Similarities between Wegovy and Ozempic

Wegovy and Ozempic share many characteristics. Here’s a closer look at the similarities between these semaglutide drugs.

Semaglutide as active ingredient

Semaglutide is the active ingredient in both Ozempic and Wegovy. This ingredient is a glucagon-like peptide-1 agonist that mimics the naturally occurring GLP-1 hormone to regulate glucose levels. It is approved for use (in different drugs) for long-term weight management or type 2 diabetes.

Semaglutide medicines regulate blood sugar levels and reduce appetite. When you eat, semaglutide slows digestion rates. It interacts with the receptors in your brain that signal fullness for longer periods. It also suppresses your hunger, so you consume less food and fewer calories.

Together, these effects often lead to weight loss while taking semaglutide.

How patients use semaglutide

Both Wegovy and Ozempic require weekly injections using a pre-filled disposable pen. Rybelsus® — another semaglutide drug — uses a daily oral tablet instead of a weekly injection.

Both Ozempic and Wegovy labels recommend starting with 0.25 mg doses, which may increase over time. Patients can inject Wegovy or Ozempic into their upper arm, abdomen or thigh. Drug makers recommend taking the drugs on the same day each week, with or without meals. It’s not required to take semaglutide injection at the same time of day.

Side effects shared by Ozempic and Wegovy

The common side effects of Ozempic or Wegovy can include diarrhea, nausea, vomiting and constipation. More serious side effects on the drugs’ labels include acute pancreatitis, acute kidney injury, bile duct blockages and gallstone attacks.

However, the Wegovy and Ozempic warning labels don’t include several concerning side effects. Patients taking these semaglutide medications have reported:

All of these are among the nearly 62,000 FDA adverse event reports for semaglutide drugs. Some of these adverse reactions may have long-term implications even after stopping the drug.

The FDA Adverse Event Monitoring System (AEMS) is intended to help identify safety concerns related to marketed products, but it doesn’t prove any product or drug is linked to or caused a particular side effect or injury. Reports by themselves aren’t an indicator of a drug’s safety profile. In addition, AEMS may include duplicate reports or may significantly undercount injuries.

Lawsuits filed over serious unlisted side effects of semaglutide

People experiencing unexpected side effects are taking action against Ozempic and Wegovy manufacturers by filing semaglutide lawsuits or other diabetes lawsuits. They want to see Novo Nordisk held accountable for aggressively marketing their products as safe and failing to warn about the associated risks of taking Ozempic or Wegovy.

Who can file a GLP-1 RA lawsuit? Individuals, or their loved ones, who suffered serious medical conditions after taking a branded GLP-1 RA drug prescribed by a doctor may be eligible to file a lawsuit. The condition must not have been on the drug’s warning label at the time of prescription.

Conditions that may be grounds for a lawsuit include:

  • Vision loss or changes
  • Ileus and intestinal blockages
  • Necrotizing pancreatitis
  • Pulmonary embolisms
  • Deep vein thrombosis (DVT)
  • Gastric distress including severe or permanent stomach paralysis
  • Surgical complications

Frequently asked questions

Is Wegovy the same as Ozempic?

No, Wegovy is not the same as Ozempic. Although they contain the same active ingredient, the primary differences between Ozempic and Wegovy are the dose of semaglutide in each pen and what each is approved to treat.

  • Wegovy treats obesity at a higher dose of semaglutide.
  • Ozempic treats type 2 diabetes at a lower dose.

Can you take Wegovy and Ozempic at the same time?

No, you shouldn’t take Ozempic and Wegovy at the same time. You should also never take other GLP-1 agonist medications while taking semaglutide. Taking more than the prescribed dosage could result in accidental overdose and severe gastrointestinal issues.

If you accidentally take more than your prescribed dose of Ozempic or Wegovy or take both at the same time, contact your healthcare provider immediately or go to a hospital. You can also call the nationwide poison control hotline at 800-222-1222.

Are Wegovy and Ozempic the same as Mounjaro and Rybelsus?

Wegovy and Ozempic aren’t the same as other GLP-1 RA medications, like Mounjaro® and Rybelsus® but they are in the same class of drugs. Wegovy, Ozempic and Rybelsus use semaglutide as the active ingredient; Mounjaro and Zepbound use tirzepatide. Mounjaro, Ozempic, Wegovy and Zepbound are taken as weekly injections; Rybelsus is taken daily as an oral tablet or shot.

 

Active ingredient

Weekly injection or daily oral tablet

Mounjaro

tirzepatide

Weekly injection

Zepbound

tirzepatide

Weekly injection

Ozempic

semaglutide

Weekly injection

Rybelsus

semaglutide

Daily as an oral tablet or injection

Wegovy

semaglutide

Weekly injection

 

Are there Ozempic and Wegovy lawsuits?

Yes, there are Ozempic and Wegovy lawsuits. People who are suing the makers of semaglutide drugs say they weren’t warned sufficiently about side effects such as vision loss and intestinal blockages. As of December 2, 2025, more than 2,900 plaintiffs had filed suit in federal court as part of In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094. Additional cases have been filed in state courts.

What’s the difference between Ozempic, Wegovy, Mounjaro and Zepbound?

Ozempic, Wegovy, Mounjaro and Zepbound are all among a group of drugs used for diabetes treatment and weight loss. The key differences between them are the active ingredient and approved uses. Here’s a brief explanation of major differences:

  • Ozempic is a semaglutide-based medicine approved for treating type 2 diabetes and preventing heart disease in adults.
  • Wegovy  is a semaglutide-based medicine approved for managing weight and preventing heart disease in people 12 or older.
  • Mounjaro is a tirzepatide-based medicine approved for treating type 2 diabetes.
  • Zepbound is a tirzepatide-based medicine approved for weight loss in adults.

Dosages may also vary between these medications. If you’re considering using any of these drugs, consult a health care professional to learn about risks and other considerations such as body mass index (BMI) and weight-related risks.

Our weight loss drug litigation experience

Motley Rice lawyers have advocated for thousands of individuals who suffer serious injuries and medical conditions as a result of dangerous over-the-counter (OTC) and prescription medication.

If you suspect your use of prescription Wegovy or Ozempic may be responsible for your intestinal blockages, gastroparesis or the death of someone you love, do not hesitate to contact our legal team to discuss your options. We may be able to help by:

  • Gathering valuable evidence to prove the manufacturers’ failure to warn
  • Investigating whether Ozempic or Wegovy is responsible for your symptoms
  • Demonstrating how Novo Nordisk may have failed to comply with FDA regulations
  • Identifying potential problems that could impact your case

Learn more about our medical drug experience here.


Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death.

Ozempic, Wegovy, Mounjaro, Rybelsus and Zepbound remain approved by the U.S. Food and Drug Administration (FDA).

Key differences between Wegovy and Ozempic

Similarities between Wegovy and Ozempic

Frequently asked questions

Our weight loss drug litigation experience

About the Author

Sources
  1. AARP. When Will Medicare Cover Ozempic, Other Weight-Loss Drugs?
  2. Brandon Richland, MD. Semaglutide Pens: Do’s and Don’t  Of Using Correctly.
  3. FDA Adverse Event Reporting System. Semagultide (G).
  4. GoodRx. How Much Does Wegovy Cost?
  5. GoodRx. How Much Ozempic Costs Without Insurance — and 9 Ways to Save.
  6. GoodRx. Where to Inject Ozempic: Does Your Stomach, Arm, or Thigh Make a Difference?
  7. Johns Hopkins Medicine. Pancreatitis.
  8. Mayo Clinic. What happens if you take too much semaglutide?
  9. Medical News Today. How to appeal Wegovy coverage denial.
  10. National Kidney Foundation. Acute Kidney Injury (AKI).
  11. Ozempic.com. Dosing for Ozempic® (semaglutide) Injection.
  12. Prime Health. HOW SEMAGLUTIDE OZEMPIC WEGOVY WORKS UNDERSTANDING THE MECHANISM BEHIND ITS WEIGHT LOSS EFFECTS.
  13. Scientific American. Ozempic and Mounjaro Aren’t the Same. Here’s How Weight-Loss Drugs Compare.
  14. United States Judicial Panel on Multidistrict Litigation. Pending MDL Reports Archive.
  15. USA Today. Medicare announces lower prices for 15 drugs including Ozempic, Wegovy.
  16. USA Today. Why does Ozempic cost so much? Senators grilled Novo Nordisk CEO for answers.
  17. U.S. Food and Drug Administration. FDA Adverse Reporting System (FAERS) Public Dashboard.
  18. U.S. Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION: MOUNJARO (tirzapetide) injection, for subcutaneous use.
  19. U.S. Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION: OZEMPIC (semaglutide) injection, for subcutaneous use.
  20. U.S. Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION: RYBELSUS (semaglutide) tablets, for oral use.
  21. U.S. Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION: WEGOVY (semaglutide) injection, for subcutaneous use.
  22. U.S. Food & Drug Administration. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss.
  23. U.S. Judicial Panel on Multidistrict Litigation. Pending MDLs.
  24. WebMD. Mounjaro, Ozempic, Wegovy, Zepbound: What’s the Difference?
  25. Wegovy.com. Wegovy® Dosing Schedule.
Your Legal Options

Start Your Motley Rice Consultation in Simple Steps

Connect with an Attorney1.800.768.4026

1

Submit Information

Call us or fill out our online form with the details of your potential case.

2

Case Review

Our team reviews your information to assess your potential case.

3

Case Consultation

Talk with us about next steps.